Research Grade Vixarelimab

Catalog No.

DHJ45501

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG4-IgG1,Lambda

Clonality

Monoclonal

Target

OSMRB, IL-31R subunit beta, Oncostatin-M-specific receptor subunit beta, Interleukin-31 receptor subunit beta, IL-31RB, IL-31R-beta, OSMR, IL-31 receptor subunit beta

Concentration

7.58 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q99650

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

100 mM Pro-Ac, 20 mM Arg, pH 5.0

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

KPL-716, 30C6 (N73D), BIIB069, BIIB-069, CAS: 2243320-83-2

Clone ID

Vixarelimab

Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature., PMID:40372666

New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review., PMID:40282922

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments., PMID:39598410

Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment., PMID:38778608

Chronic Prurigo., PMID:38722190

Prurigo nodularis: new insights into pathogenesis and novel therapeutics., PMID:38345154

A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis., PMID:38332383

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments., PMID:37717255

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study., PMID:36816342

Document Download

Research Grade Vixarelimab.pdf